{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:46:01Z","timestamp":1785843961435,"version":"3.56.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this review is to summarize current knowledge on the diagnostic and therapeutic significance of antibodies against advanced glycation end-products (anti-AGEs). AGEs are formed through non-enzymatic reactions of reducing sugars with proteins, lipids, and nucleic acids, and their accumulation has been implicated in the pathogenesis of chronic diseases such as diabetes, atherosclerosis, cancer, and neurodegenerative disorders. This paper discusses anti-MGO modified proteins, anti-imidazolone, anti-pentosidine, anti-CML (including SIWA318H), anti-CEL, anti-CMA, and anti-GA-pyridine antibodies, with a focus on their potential applications in diagnostics (biomarkers, disease progression monitoring) and therapy (e.g., SIWA318H in pancreatic cancer). The review also highlights current limitations, particularly regarding clinical use in humans, and outlines perspectives for further research in this promising field.<\/jats:p>","DOI":"10.1007\/s11033-026-12545-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:18:16Z","timestamp":1785842296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and therapeutic significance of selected antibodies against advanced glycation end-products (anti-AGEs)"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9492-3502","authenticated-orcid":false,"given":"Julia","family":"Sobczy\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Federowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Gali\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Ziomek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Stach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Bronowicka-Szyde\u0142ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Madziarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"12545_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s12276-021-00561-7","volume":"53","author":"W Rungratanawanich","year":"2021","unstructured":"Rungratanawanich W, Qu Y, Wang X et al (2021) Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 53:168\u2013188. https:\/\/doi.org\/10.1038\/s12276-021-00561-7","journal-title":"Exp Mol Med"},{"key":"12545_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10557-024-07639-0","volume":"39","author":"B Wang","year":"2025","unstructured":"Wang B, Jiang T, Qi Y et al (2025) AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications. Cardiovasc Drugs Ther 39:1489\u20131506. https:\/\/doi.org\/10.1007\/s10557-024-07639-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"12545_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/1559827617708991","volume":"13","author":"C Prasad","year":"2017","unstructured":"Prasad C, Davis KE, Imrhan V, Juma S, Vijayagopal P (2017) Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification. Am J Lifestyle Med 13(4):384\u2013404. https:\/\/doi.org\/10.1177\/1559827617708991","journal-title":"Am J Lifestyle Med"},{"issue":"sup1","key":"12545_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/10715762.2013.815348","volume":"47","author":"G Vistoli","year":"2013","unstructured":"Vistoli G, De Maddis D, Cipak A, Zarkovic N, Carini M, Aldini G (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 47(sup1):3\u201327. https:\/\/doi.org\/10.3109\/10715762.2013.815348","journal-title":"Free Radic Res"},{"issue":"1","key":"12545_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","volume":"48","author":"JW Baynes","year":"1999","unstructured":"Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48(1):1\u20139. https:\/\/doi.org\/10.2337\/diabetes.48.1.1","journal-title":"Diabetes"},{"key":"12545_CR6","doi-asserted-by":"publisher","first-page":"101083","DOI":"10.1016\/j.redox.2018.101083","volume":"23","author":"M Mol","year":"2018","unstructured":"Mol M, Degani G, Coppa C, Baron G, Popolo L, Carini M, Aldini G, Vistoli G, Altomare A (2018) Advanced lipoxidation end products (ALEs) as RAGE binders: Mass spectrometric and computational studies to explain the reasons why. Redox Biol 23:101083. https:\/\/doi.org\/10.1016\/j.redox.2018.101083","journal-title":"Redox Biol"},{"key":"12545_CR7","doi-asserted-by":"publisher","unstructured":"Moldogazieva NT, Mokhosoev IM, Mel\u2019nikova TI, Porozov YB, Terentiev AA (2019) Oxidative Stress and Advanced Lipoxidation and Glycation end Products (ALEs and AGEs) in aging and Age-Related Diseases. Oxidative Medicine and Cellular Longevity, 2019, 1\u201314. https:\/\/doi.org\/10.1155\/2019\/3085756","DOI":"10.1155\/2019\/3085756"},{"issue":"sup1","key":"12545_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/10715762.2013.792926","volume":"47","author":"G Aldini","year":"2013","unstructured":"Aldini G, Vistoli G, Stefek M, Chondrogianni N, Grune T, Sereikaite J, Sadowska-Bartosz I, Bartosz G (2013) Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic Res 47(sup1):93\u2013137. https:\/\/doi.org\/10.3109\/10715762.2013.792926","journal-title":"Free Radic Res"},{"issue":"3","key":"12545_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/biomedicines10030696","volume":"10","author":"A Bianco","year":"2022","unstructured":"Bianco A, Tiribelli C, Bellarosa C (2022) Translational approach to the Protective Effect of bilirubin in Diabetic kidney Disease. Biomedicines 10(3):696. https:\/\/doi.org\/10.3390\/biomedicines10030696","journal-title":"Biomedicines"},{"issue":"4","key":"12545_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2337\/diabetes.48.4.870","volume":"48","author":"VM Monnier","year":"1999","unstructured":"Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S, DCCT Skin Collagen Ancillary Study Group (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes Control Complications Trial Diabetes 48(4):870\u2013880. https:\/\/doi.org\/10.2337\/diabetes.48.4.870","journal-title":"Diabetes Control Complications Trial Diabetes"},{"issue":"2","key":"12545_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1089\/rej.2006.9.264","volume":"9","author":"VM Monnier","year":"2006","unstructured":"Monnier VM, Sell DR (2006) Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuven Res 9(2):264\u2013273. https:\/\/doi.org\/10.1089\/rej.2006.9.264","journal-title":"Rejuven Res"},{"issue":"4","key":"12545_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1389450054021873","volume":"6","author":"M Thomas","year":"2005","unstructured":"Thomas M, Baynes J, Thorpe S, Cooper M (2005) The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6(4):453\u2013474. https:\/\/doi.org\/10.2174\/1389450054021873","journal-title":"Curr Drug Targets"},{"issue":"1","key":"12545_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.abb.2003.08.010","volume":"419","author":"T Miyata","year":"2003","unstructured":"Miyata T, Van Strihou Y, C (2003) Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 419(1):50\u201354. https:\/\/doi.org\/10.1016\/j.abb.2003.08.010","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"12545_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/bjp.2008.121","volume":"154","author":"M Montagnani","year":"2008","unstructured":"Montagnani M (2008) Diabetic cardiomyopathy: how much does it depend on AGE? Br J Pharmacol 154(4):725\u2013726. https:\/\/doi.org\/10.1038\/bjp.2008.121","journal-title":"Br J Pharmacol"},{"issue":"3","key":"12545_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cardfail.2004.09.010","volume":"11","author":"WC Little","year":"2005","unstructured":"Little WC, Zile MR, Kitzman DW, Hundley WG, O\u2019Brien TX, deGroof RC (2005) The effect of alagebrium chloride (ALT-711), a novel glucose Cross-Link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11(3):191\u2013195. https:\/\/doi.org\/10.1016\/j.cardfail.2004.09.010","journal-title":"J Card Fail"},{"issue":"12","key":"12545_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.ejheart.2007.09.009","volume":"9","author":"JW Hartog","year":"2007","unstructured":"Hartog JW, Voors AA, Bakker SJ, Smit AJ, Van Veldhuisen DJ (2007) Advanced Glycation End-Products (AGEs) and heart Failure: Pathophysiology and clinical implications. Eur J Heart Fail 9(12):1146\u20131155. https:\/\/doi.org\/10.1016\/j.ejheart.2007.09.009","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"12545_CR17","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.amjhyper.2004.08.022","volume":"17","author":"G Bakris","year":"2004","unstructured":"Bakris G, Bank A, Kass D, Neutel J, Preston R, Oparil S (2004) Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17(12):S23\u2013S30. https:\/\/doi.org\/10.1016\/j.amjhyper.2004.08.022","journal-title":"Am J Hypertens"},{"issue":"8","key":"12545_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/eurjhf\/hfr067","volume":"13","author":"JW Hartog","year":"2011","unstructured":"Hartog JW, Willemsen S, Van Veldhuisen DJ, Posma JL, Van Wijk LM, Hummel YM, Hillege HL, Voors AA, Investigators FTB (2011) Effects of Alagebrium, an Advanced Glycation Endproduct Breaker, on Exercise Tolerance and Cardiac Function in Patients with Chronic Heart Failure. Eur J Heart Fail 13(8):899\u2013908. https:\/\/doi.org\/10.1093\/eurjhf\/hfr067","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"12545_CR19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s001250051355","volume":"43","author":"ME Cooper","year":"2000","unstructured":"Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T (2000) The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43(5):660\u2013664. https:\/\/doi.org\/10.1007\/s001250051355","journal-title":"Diabetologia"},{"issue":"7","key":"12545_CR20","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1902\/jop.2014.130554","volume":"85","author":"P Chang","year":"2014","unstructured":"Chang P, Tsai S, Chong LY, Kao M (2014) N-Phenacylthiazolium bromide inhibits the advanced glycation end product (AGE)\u2013AGE receptor axis to modulate experimental periodontitis in rats. J Periodontol 85(7):e268\u2013e276. https:\/\/doi.org\/10.1902\/jop.2014.130554","journal-title":"J Periodontol"},{"issue":"7","key":"12545_CR21","doi-asserted-by":"publisher","first-page":"e103199","DOI":"10.1371\/journal.pone.0103199","volume":"9","author":"BS Bradke","year":"2014","unstructured":"Bradke BS, Vashishth D (2014) N-Phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycation. PLoS ONE 9(7):e103199. https:\/\/doi.org\/10.1371\/journal.pone.0103199","journal-title":"PLoS ONE"},{"issue":"3","key":"12545_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/01.asn.0000051593.41395.b9","volume":"14","author":"J Uribarri","year":"2003","unstructured":"Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14(3):728\u2013731. https:\/\/doi.org\/10.1097\/01.asn.0000051593.41395.b9","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"12545_CR23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1210\/jc.2007-1817","volume":"93","author":"S Goh","year":"2008","unstructured":"Goh S, Cooper ME (2008) The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metabolism 93(4):1143\u20131152. https:\/\/doi.org\/10.1210\/jc.2007-1817","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"22","key":"12545_CR24","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1161\/01.cir.0000039325.03698.36","volume":"106","author":"LG Bucciarelli","year":"2002","unstructured":"Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E\u2013Null mice. Circulation 106(22):2827\u20132835. https:\/\/doi.org\/10.1161\/01.cir.0000039325.03698.36","journal-title":"Circulation"},{"issue":"12","key":"12545_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2337\/diacare.15.12.1835","volume":"15","author":"M Brownlee","year":"1992","unstructured":"Brownlee M (1992) Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835\u20131843. https:\/\/doi.org\/10.2337\/diacare.15.12.1835","journal-title":"Diabetes Care"},{"issue":"8","key":"12545_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00394-009-0038-6","volume":"48","author":"T Gawlowski","year":"2009","unstructured":"Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, Vlassara H, Koschinsky T, Tschoepe D (2009) Advanced glycation end products strongly activate platelets. Eur J Nutr 48(8):475\u2013481. https:\/\/doi.org\/10.1007\/s00394-009-0038-6","journal-title":"Eur J Nutr"},{"issue":"1\u20132","key":"12545_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.vetimm.2011.12.016","volume":"145","author":"M De Laat","year":"2011","unstructured":"De Laat M, Kyaw-Tanner M, Sillence M, McGowan C, Pollitt C (2011) Advanced glycation endproducts in horses with insulin-induced laminitis. Vet Immunol Immunopathol 145(1\u20132):395\u2013401. https:\/\/doi.org\/10.1016\/j.vetimm.2011.12.016","journal-title":"Vet Immunol Immunopathol"},{"issue":"2","key":"12545_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1476-5381.2010.00905.x","volume":"161","author":"E Sick","year":"2010","unstructured":"Sick E, Brehin S, Andr\u00e9 P, Coupin G, Landry Y, Takeda K, Gies J (2010) Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 161(2):442\u2013455. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00905.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"12545_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/circulationaha.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Adv Glycation end Prod Circulation 114(6):597\u2013605. https:\/\/doi.org\/10.1161\/circulationaha.106.621854","journal-title":"Adv Glycation end Prod Circulation"},{"issue":"3","key":"12545_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1533317506289277","volume":"21","author":"T Sato","year":"2006","unstructured":"Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M (2006) Toxic Advanced Glycation End Products (TAGE) theory in Alzheimer\u2019s disease. Am J Alzheimer S Disease Other Dementias\u00ae 21(3):197\u2013208. https:\/\/doi.org\/10.1177\/1533317506289277","journal-title":"Am J Alzheimer S Disease Other Dementias\u00ae"},{"issue":"28","key":"12545_CR31","doi-asserted-by":"publisher","first-page":"25783","DOI":"10.1074\/jbc.m210433200","volume":"278","author":"E McRobert","year":"2003","unstructured":"McRobert E, Gallicchio M, Jerums G, Cooper ME, Bach LA (2003) The amino-terminal domains of the Ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. J Biol Chem 278(28):25783\u201325789. https:\/\/doi.org\/10.1074\/jbc.m210433200","journal-title":"J Biol Chem"},{"issue":"3","key":"12545_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1042\/bj20021371","volume":"370","author":"H Yonekura","year":"2003","unstructured":"Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370(3):1097\u20131109. https:\/\/doi.org\/10.1042\/bj20021371","journal-title":"Biochem J"},{"issue":"10","key":"12545_CR33","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22(10):3716\u20133727. https:\/\/doi.org\/10.1096\/fj.08-109033","journal-title":"FASEB J"},{"issue":"12","key":"12545_CR34","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1161\/01.atv.0000190660.32863.cd","volume":"25","author":"H Koyama","year":"2005","unstructured":"Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y, Arteriosclerosis (2005) Thromb Vascular Biology, 25(12), 2587\u20132593. https:\/\/doi.org\/10.1161\/01.atv.0000190660.32863.cd","journal-title":"Thromb Vascular Biology"},{"issue":"23","key":"12545_CR35","doi-asserted-by":"publisher","first-page":"12057","DOI":"10.1074\/jbc.m115.702399","volume":"291","author":"A Braley","year":"2016","unstructured":"Braley A, Kwak T, Jules J, Harja E, Landgraf R, Hudson BI (2016) Regulation of receptor for Advanced glycation end Products (RAGE) ectodomain shedding and its role in cell function. J Biol Chem 291(23):12057\u201312073. https:\/\/doi.org\/10.1074\/jbc.m115.702399","journal-title":"J Biol Chem"},{"issue":"7","key":"12545_CR36","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms23073645","volume":"23","author":"J Wautier","year":"2022","unstructured":"Wautier J, Wautier M (2022b) Vascular permeability in diseases. Int J Mol Sci 23(7):3645. https:\/\/doi.org\/10.3390\/ijms23073645","journal-title":"Int J Mol Sci"},{"issue":"2","key":"12545_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2008.01.015","volume":"201","author":"S Bro","year":"2008","unstructured":"Bro S, Flyvbjerg A, Binder CJ, Bang CA, Denner L, Olgaard K, Nielsen LB (2008) A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 201(2):274\u2013280. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.01.015","journal-title":"Atherosclerosis"},{"issue":"1","key":"12545_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/diabetes.53.1.166","volume":"53","author":"A Flyvbjerg","year":"2004","unstructured":"Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R (2004) Long-Term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53(1):166\u2013172. https:\/\/doi.org\/10.2337\/diabetes.53.1.166","journal-title":"Diabetes"},{"issue":"3","key":"12545_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1677\/joe.1.06524","volume":"188","author":"LJN Jensen","year":"2006","unstructured":"Jensen LJN, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A (2006) Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol 188(3):493\u2013501. https:\/\/doi.org\/10.1677\/joe.1.06524","journal-title":"J Endocrinol"},{"issue":"8","key":"12545_CR40","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1681\/asn.v1482109","volume":"14","author":"AS De Vriese","year":"2003","unstructured":"De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH (2003) Inhibition of the interaction of AGE\u2013RAGE prevents Hyperglycemia-Induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 14(8):2109\u20132118. https:\/\/doi.org\/10.1681\/asn.v1482109","journal-title":"J Am Soc Nephrol"},{"issue":"1\u20133","key":"12545_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejphar.2008.10.031","volume":"600","author":"MV Gangoiti","year":"2008","unstructured":"Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD (2008) Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 600(1\u20133):140\u2013147. https:\/\/doi.org\/10.1016\/j.ejphar.2008.10.031","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"12545_CR42","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/01.atv.0000249630.02085.12","volume":"26","author":"C Cuccurullo","year":"2006","unstructured":"Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F (2006) Suppression of rage as a basis of Simvastatin-Dependent plaque stabilization in Type 2 diabetes. Arterioscler Thromb Vascular Biology 26(12):2716\u20132723. https:\/\/doi.org\/10.1161\/01.atv.0000249630.02085.12","journal-title":"Arterioscler Thromb Vascular Biology"},{"issue":"7","key":"12545_CR43","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/10408398.2017.1396200","volume":"59","author":"M Alizadeh","year":"2017","unstructured":"Alizadeh M, Kheirouri S (2017) Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents. Crit Rev Food Sci Nutr 59(7):1169\u20131177. https:\/\/doi.org\/10.1080\/10408398.2017.1396200","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"9","key":"12545_CR44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3109\/10715762.2010.495127","volume":"44","author":"S Grimm","year":"2010","unstructured":"Grimm S, Ernst L, Gr\u00f6tzinger N, H\u00f6hn A, Breusing N, Reinheckel T, Grune T (2010) Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. Free Radic Res 44(9):1013\u20131026. https:\/\/doi.org\/10.3109\/10715762.2010.495127","journal-title":"Free Radic Res"},{"issue":"3\u20134","key":"12545_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00726-003-0029-5","volume":"25","author":"S Horiuchi","year":"2003","unstructured":"Horiuchi S, Sakamoto Y, Sakai M (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25(3\u20134):283\u2013292. https:\/\/doi.org\/10.1007\/s00726-003-0029-5","journal-title":"Amino Acids"},{"issue":"12","key":"12545_CR46","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1634\/theoncologist.2018-0786","volume":"24","author":"P Rochefort","year":"2019","unstructured":"Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, De La Fouchardi\u00e8re C (2019) Long-Term survivors in Metastatic Pancreatic ductal adenocarcinoma: A retrospective and matched pair analysis. Oncologist 24(12):1543\u20131548. https:\/\/doi.org\/10.1634\/theoncologist.2018-0786","journal-title":"Oncologist"},{"issue":"3","key":"12545_CR47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/pathophysiology29030034","volume":"29","author":"K Kostov","year":"2022","unstructured":"Kostov K, Blazhev A (2022) Elevated IgG and IgM Autoantibodies to Advanced Glycation End Products of Vascular Elastin in Hypertensive Patients with Type 2 Diabetes: Relevance to Disease Initiation and Progression. Pathophysiology 29(3):426\u2013434. https:\/\/doi.org\/10.3390\/pathophysiology29030034","journal-title":"Pathophysiology"},{"issue":"2","key":"12545_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cellimm.2014.12.007","volume":"293","author":"JM Ashraf","year":"2015","unstructured":"Ashraf JM, Arfat MY, Arif Z, Ahmad J, Moinuddin, Alam K (2015) A clinical correlation of anti-DNA-AGE autoantibodies in type 2 diabetes mellitus with disease duration. Cell Immunol 293(2):74\u201379. https:\/\/doi.org\/10.1016\/j.cellimm.2014.12.007","journal-title":"Cell Immunol"},{"issue":"4","key":"12545_CR49","doi-asserted-by":"publisher","first-page":"e003480","DOI":"10.1136\/rmdopen-2023-003480","volume":"9","author":"MD Van Den Beukel","year":"2023","unstructured":"Van Den Beukel MD, Van Wesemael TJ, Hoogslag ATW, Borggreven NV, Huizinga TW, Mil VDH-V, Toes AH, Van Der Woude RE, D., Trouw LA (2023) Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open 9(4):e003480. https:\/\/doi.org\/10.1136\/rmdopen-2023-003480","journal-title":"RMD Open"},{"key":"12545_CR50","doi-asserted-by":"publisher","first-page":"1195747","DOI":"10.3389\/fmed.2023.1195747","volume":"10","author":"MD Van Den Beukel","year":"2023","unstructured":"Van Den Beukel MD, Stoelinga AEC, Van Der Meer AJ, Van Der Meulen S, Zhang L, Tushuizen ME, Van Hoek B, Trouw LA (2023) Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment. Front Med 10:1195747. https:\/\/doi.org\/10.3389\/fmed.2023.1195747","journal-title":"Front Med"},{"issue":"1","key":"12545_CR51","doi-asserted-by":"publisher","first-page":"16953","DOI":"10.1038\/s41598-023-44211-6","volume":"13","author":"GR Rossi","year":"2023","unstructured":"Rossi GR, Jensen A, Ng S, Yin Z, Li A, Misra A, Von Hoff DD, Gruber L, Gruber M, Han H (2023) Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. Sci Rep 13(1):16953. https:\/\/doi.org\/10.1038\/s41598-023-44211-6","journal-title":"Sci Rep"},{"issue":"1","key":"12545_CR52","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/s41598-020-73877-5","volume":"10","author":"E Kor\u00e7a","year":"2020","unstructured":"Kor\u00e7a E, Piskovatska V, B\u00f6rgermann J, Santos AN, Simm A (2020) Circulating antibodies against age-modified proteins in patients with coronary atherosclerosis. Sci Rep 10(1):17105. https:\/\/doi.org\/10.1038\/s41598-020-73877-5","journal-title":"Sci Rep"},{"key":"12545_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clinbiochem.2018.04.009","volume":"56","author":"C Lin","year":"2018","unstructured":"Lin C, Sheu J, Tsai I, Wang S, Yang L, Hsu I, Chang H, Lee H, Kao S, Lee C, Chen C, Lin Y (2018) Elevated IgM against N\u03b5-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141\u2013147 in Taiwanese with Alzheimer\u2019s disease. Clin Biochem 56:75\u201382. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.04.009","journal-title":"Clin Biochem"},{"issue":"2","key":"12545_CR54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/bj3240565","volume":"324","author":"MU Ahmed","year":"1997","unstructured":"Ahmed MU, Frye EB, Degenhardt TP, Thorpe SR, Baynes JW (1997) N \u03b5-(Carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324(2):565\u2013570. https:\/\/doi.org\/10.1042\/bj3240565","journal-title":"Biochem J"},{"key":"12545_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2015.12.004","volume":"453","author":"AR Mir","year":"2015","unstructured":"Mir AR, Moinuddin, Islam S (2015) Circulating autoantibodies in cancer patients have high specificity for glycoxidation modified histone H2A. Clin Chim Acta 453:48\u201355. https:\/\/doi.org\/10.1016\/j.cca.2015.12.004","journal-title":"Clin Chim Acta"},{"issue":"37","key":"12545_CR56","doi-asserted-by":"publisher","first-page":"9228","DOI":"10.1073\/pnas.1802901115","volume":"115","author":"JJ Galligan","year":"2018","unstructured":"Galligan JJ, Wepy JA, Streeter MD, Kingsley PJ, Mitchener MM, Wauchope OR, Beavers WN, Rose KL, Wang T, Spiegel DA, Marnett LJ (2018) Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks. Proc Natl Acad Sci 115(37):9228\u20139233. https:\/\/doi.org\/10.1073\/pnas.1802901115","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"12545_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2796.2011.02411.x","volume":"271","author":"D Engelbertsen","year":"2011","unstructured":"Engelbertsen D, Anand DV, Fredrikson GN, Hopkins D, Corder R, Shah PK, Lahiri A, Nilsson J, Bengtsson E (2011) High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J Intern Med 271(1):82\u201389. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02411.x","journal-title":"J Intern Med"},{"issue":"7","key":"12545_CR58","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.4049\/jimmunol.1402869","volume":"195","author":"D Engelbertsen","year":"2015","unstructured":"Engelbertsen D, Vallejo J, Qu\u00e1ch TD, Fredrikson GN, Alm R, Hedblad B, Bj\u00f6rkbacka H, Rothstein TL, Nilsson J, Bengtsson E (2015) Low Levels of IgM Antibodies against an Advanced Glycation Endproduct\u2013Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects. J Immunol 195(7):3020\u20133025. https:\/\/doi.org\/10.4049\/jimmunol.1402869","journal-title":"J Immunol"},{"issue":"1\u20132","key":"12545_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.12.020","volume":"332","author":"R Nagai","year":"2008","unstructured":"Nagai R, Fujiwara Y, Mera K, Yamagata K, Sakashita N, Takeya M (2008) Immunochemical detection of N\u03b5-(carboxyethyl)lysine using a specific antibody. J Immunol Methods 332(1\u20132):112\u2013120. https:\/\/doi.org\/10.1016\/j.jim.2007.12.020","journal-title":"J Immunol Methods"},{"issue":"2","key":"12545_CR60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.bbrc.2011.03.040","volume":"407","author":"K Mera","year":"2011","unstructured":"Mera K, Nagai R, Takeo K, Izumi M, Maruyama T, Otagiri M (2011) An autoantibody against N\u03b5-(carboxyethyl)lysine (CEL): Possible involvement in the removal of CEL-modified proteins by macrophages. Biochem Biophys Res Commun 407(2):420\u2013425. https:\/\/doi.org\/10.1016\/j.bbrc.2011.03.040","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"12545_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jid.2022.08.051","volume":"143","author":"G Macchiarella","year":"2022","unstructured":"Macchiarella G, Cornacchione V, Cojean C, Riker J, Wang Y, Te H, Ceci M, Gudjonsson JE, Gaulis S, Goetschy JF, Wollschlegel A, Gass SK, Oetliker-Contin S, Wettstein-Ling B, Schaefer DJ, Meschberger P, De Roche R, Osinga R, Wieczorek G, Roediger B (2022) Disease association of Anti\u2013Carboxyethyl lysine autoantibodies in hidradenitis suppurativa. J Invest Dermatology 143(2):273\u2013283e12. https:\/\/doi.org\/10.1016\/j.jid.2022.08.051","journal-title":"J Invest Dermatology"},{"issue":"6","key":"12545_CR62","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1172\/jci119285","volume":"99","author":"T Niwa","year":"1997","unstructured":"Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y (1997) Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99(6):1272\u20131280. https:\/\/doi.org\/10.1172\/jci119285","journal-title":"J Clin Invest"},{"issue":"4","key":"12545_CR63","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000190218","volume":"76","author":"T Niwa","year":"1997","unstructured":"Niwa T (1997) \u03b22-Microglobulin Dialysis Amyloid and Its Formation: Role of 3-Deoxyglucosone and Advanced Glycation End Products. Nephron 76(4):373\u2013391. https:\/\/doi.org\/10.1159\/000190218","journal-title":"Nephron"},{"issue":"1\u20132","key":"12545_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0009-8981(00)00299-0","volume":"300","author":"S Franke","year":"2000","unstructured":"Franke S, Niwa T, Deuther-Conrad W, Sommer M, Hein G, Stein G (2000) Immunochemical detection of imidazolone in uremia and rheumatoid arthritis. Clin Chim Acta 300(1\u20132):29\u201341. https:\/\/doi.org\/10.1016\/s0009-8981(00)00299-0","journal-title":"Clin Chim Acta"},{"issue":"1","key":"12545_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0378-4347(99)00113-9","volume":"731","author":"T Niwa","year":"1999","unstructured":"Niwa T (1999) 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomedical Sci Appl 731(1):23\u201336. https:\/\/doi.org\/10.1016\/s0378-4347(99)00113-9","journal-title":"J Chromatogr B Biomedical Sci Appl"},{"issue":"4","key":"12545_CR66","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/dmr.5610070404","volume":"7","author":"DR Sell","year":"1991","unstructured":"Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J, Monnier VM (1991) Pentosidine: A molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Res Rev 7(4):239\u2013251. https:\/\/doi.org\/10.1002\/dmr.5610070404","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"12545_CR67","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1046\/j.1523-1755.1998.00756.x","volume":"53","author":"T Miyata","year":"1998","unstructured":"Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, Van Ypersele C, Kurokawa K (1998) Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 53(2):416\u2013422. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00756.x","journal-title":"Kidney Int"},{"issue":"9","key":"12545_CR68","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/clinchem\/40.9.1766","volume":"40","author":"S Taneda","year":"1994","unstructured":"Taneda S, Monnier VM (1994) ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 40(9):1766\u20131773. https:\/\/doi.org\/10.1093\/clinchem\/40.9.1766","journal-title":"Clin Chem"},{"issue":"4","key":"12545_CR69","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1681\/asn.v104822","volume":"10","author":"D Suzuki","year":"1999","unstructured":"Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10(4):822\u2013832. https:\/\/doi.org\/10.1681\/asn.v104822","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"12545_CR70","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/bbrc.1997.6944","volume":"236","author":"K Horie","year":"1997","unstructured":"Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K (1997) Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer\u2019s disease and aged neurons. Biochem Biophys Res Commun 236(2):327\u2013332. https:\/\/doi.org\/10.1006\/bbrc.1997.6944","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"12545_CR71","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.diabres.2013.01.019","volume":"100","author":"K Munenori","year":"2013","unstructured":"Munenori K, Kitazawa R, Makita K, Yoshida K, Takeji M, Soga Y, Kurata M, Haraguchi R, Kitazawa S (2013) Pulmonary hypertension associated with diffuse deposition of pentosidine in pulmonary arterioles. Diabetes Res Clin Pract 100(2):e59\u2013e62. https:\/\/doi.org\/10.1016\/j.diabres.2013.01.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"12545_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1440-1827.1998.tb03953.x","volume":"48","author":"T Kimura","year":"1998","unstructured":"Kimura T, Takamatsu J, Miyata T, Miyakawa T, Horiuchi S (1998) Localization of identified advanced glycation end-product structures, N\u03b5=(carboxymethyl)lysine and pentosidine, in age\u2010related inclusions in human brains. Pathol Int 48(8):575\u2013579. https:\/\/doi.org\/10.1111\/j.1440-1827.1998.tb03953.x","journal-title":"Pathol Int"},{"issue":"3","key":"12545_CR73","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/ndt\/14.3.576","volume":"14","author":"Y Izuhara","year":"1999","unstructured":"Izuhara Y, Miyata T, Ueda Y, Suzuki D, Asahi K, Inagi R, Sakai H, Kurokawa K (1999) A Sensitive and specific ELISA for plasma pentosidine. Nephrol Dialysis Transplantation 14(3):576\u2013580. https:\/\/doi.org\/10.1093\/ndt\/14.3.576","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"6","key":"12545_CR74","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3177\/jnsv.65.526","volume":"65","author":"S Kashiwabara","year":"2019","unstructured":"Kashiwabara S, Hosoe H, Ohno R, Nagai R, Shiraki M (2019) Development and evaluation of novel ELISA for determination of urinary pentosidine. J Nutri Sci Vitaminol 65(6):526\u2013533. https:\/\/doi.org\/10.3177\/jnsv.65.526","journal-title":"J Nutri Sci Vitaminol"},{"issue":"3","key":"12545_CR75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1525-1594.2009.00801.x","volume":"34","author":"Y Zhou","year":"2010","unstructured":"Zhou Y, Yu Z, Jia H, Sun F, Ma L, Guo R, Peng L, Cui T (2010) Association of serum pentosidine with arterial stiffness in hemodialysis patients. Artif Organs 34(3):193\u2013199. https:\/\/doi.org\/10.1111\/j.1525-1594.2009.00801.x","journal-title":"Artif Organs"},{"issue":"1","key":"12545_CR76","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12891-021-04279-5","volume":"22","author":"K Moriwaki","year":"2021","unstructured":"Moriwaki K, Matsumoto H, Tanimura C, Osaki M, Nagashima H, Hagino H (2021) Urinary pentosidine level is associated with grip strength and gait speed in community-dwelling adults: a cross-sectional study. BMC Musculoskelet Disord 22(1):392. https:\/\/doi.org\/10.1186\/s12891-021-04279-5","journal-title":"BMC Musculoskelet Disord"},{"key":"12545_CR77","doi-asserted-by":"publisher","unstructured":"Schalkwijk CG, Baidoshvili A, Stehouwer CD, Van Hinsbergh VW, Niessen HW (2004) Increased accumulation of the glycoxidation product N\u03b5-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochimica Et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1636(2\u20133):82\u201389. https:\/\/doi.org\/10.1016\/j.bbalip.2003.07.002","DOI":"10.1016\/j.bbalip.2003.07.002"},{"issue":"1\u20132","key":"12545_CR78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s0165-0173(96)00016-1","volume":"23","author":"G M\u00fcnch","year":"1997","unstructured":"M\u00fcnch G, Thome J, Foley P, Schinzel R, Riederer P (1997b) Advanced glycation endproducts in ageing and Alzheimer\u2019s disease. Brain Res Rev 23(1\u20132):134\u2013143. https:\/\/doi.org\/10.1016\/s0165-0173(96)00016-1","journal-title":"Brain Res Rev"},{"issue":"13","key":"12545_CR79","doi-asserted-by":"publisher","first-page":"12087","DOI":"10.1074\/jbc.m406313200","volume":"280","author":"Z Alikhani","year":"2004","unstructured":"Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT (2004) Advanced Glycation End Products Enhance Expression of Pro-apoptotic Genes and Stimulate Fibroblast Apoptosis through Cytoplasmic and Mitochondrial Pathways. J Biol Chem 280(13):12087\u201312095. https:\/\/doi.org\/10.1074\/jbc.m406313200","journal-title":"J Biol Chem"},{"key":"12545_CR80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbrep.2016.03.011","volume":"6","author":"AB Finco","year":"2016","unstructured":"Finco AB, Machado-De-\u00c1vila RA, Maciel R, De Moura J, Billiald P, Stinghen AEM, Alvarenga LM (2016) Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease. Biochem Biophys Rep 6:142\u2013148. https:\/\/doi.org\/10.1016\/j.bbrep.2016.03.011","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"12545_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1196\/annals.1433.001","volume":"1126","author":"R Nagai","year":"2008","unstructured":"Nagai R, Fujiwara Y, Mera K, Motomura K, Iwao Y, Tsurushima K, Nagai M, Takeo K, Yoshitomi M, Otagiri M, Ikeda T (2008) Usefulness of antibodies for evaluating the biological significance of AGEs. Ann N Y Acad Sci 1126(1):38\u201341. https:\/\/doi.org\/10.1196\/annals.1433.001","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"12545_CR82","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.2337\/diabetes.48.9.1842","volume":"48","author":"R Shibayama","year":"1999","unstructured":"Shibayama R, Araki N, Nagai R, Horiuchi S (1999) Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 48(9):1842\u20131849. https:\/\/doi.org\/10.2337\/diabetes.48.9.1842","journal-title":"Diabetes"},{"issue":"6","key":"12545_CR83","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/jb\/mvh193","volume":"136","author":"W Koito","year":"2004","unstructured":"Koito W (2004) Conventional Antibody against N\u03b5-(Carboxymethyl)Lysine (CML) Shows Cross-Reaction to N\u03b5-(Carboxyethyl)Lysine (CEL): Immunochemical Quantification of CML with a Specific Antibody. J Biochem 136(6):831\u2013837. https:\/\/doi.org\/10.1093\/jb\/mvh193","journal-title":"J Biochem"},{"key":"12545_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9073451","volume":"2019","author":"S Kinoshita","year":"2019","unstructured":"Kinoshita S, Mera K, Ichikawa H, Shimasaki S, Nagai M, Taga Y, Iijima K, Hattori S, Fujiwara Y, Shirakawa J, Nagai R (2019) N\u03c9-(Carboxymethyl)arginine Is One of the Dominant Advanced Glycation End Products in Glycated Collagens and Mouse Tissues. Oxidative Med Cell Longev 2019:1\u201314. https:\/\/doi.org\/10.1155\/2019\/9073451","journal-title":"Oxidative Med Cell Longev"},{"issue":"1","key":"12545_CR85","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1196\/annals.1433.000","volume":"1126","author":"K Mera","year":"2008","unstructured":"Mera K, Fujiwara Y, Otagiri M, Sakata N, Nagai R (2008) Immunological Detection of N\u03c9-(Carboxymethyl)arginine by a Specific Antibody. Ann N Y Acad Sci 1126(1):155\u2013157. https:\/\/doi.org\/10.1196\/annals.1433.000","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"12545_CR86","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jb\/mvab056","volume":"170","author":"Y Kobashigawa","year":"2021","unstructured":"Kobashigawa Y, Ohara T, Morita K, Toyota Y, Nakamura T, Kotani S, Arimori T, Yamauchi S, Liu C, Kitazaki M, Wakeyama-Miyazaki Y, Suwa Y, Uchida-Kamekura M, Fukuda N, Sato T, Nakajima M, Takagi J, Yamagata Y, Morioka H (2021) Molecular recognition of a single-chain Fv antibody specific for GA-pyridine, an advanced glycation end-product (AGE), elucidated using biophysical techniques and synthetic antigen analogues. J Biochem 170(3):379\u2013387. https:\/\/doi.org\/10.1093\/jb\/mvab056","journal-title":"J Biochem"},{"issue":"6","key":"12545_CR87","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.acthis.2010.06.007","volume":"113","author":"J Hirose","year":"2010","unstructured":"Hirose J, Yamabe S, Takada K, Okamoto N, Nagai R, Mizuta H (2010) Immunohistochemical distribution of advanced glycation end products (AGEs) in human osteoarthritic cartilage. Acta Histochem 113(6):613\u2013618. https:\/\/doi.org\/10.1016\/j.acthis.2010.06.007","journal-title":"Acta Histochem"},{"issue":"50","key":"12545_CR88","doi-asserted-by":"publisher","first-page":"48905","DOI":"10.1074\/jbc.m205688200","volume":"277","author":"R Nagai","year":"2002","unstructured":"Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S (2002) Identification in Human Atherosclerotic Lesions of GA-pyridine, a Novel Structure Derived from Glycolaldehyde-modified Proteins. J Biol Chem 277(50):48905\u201348912. https:\/\/doi.org\/10.1074\/jbc.m205688200","journal-title":"J Biol Chem"},{"issue":"11","key":"12545_CR89","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.joca.2006.04.012","volume":"14","author":"S Wimsey","year":"2006","unstructured":"Wimsey S, Lien C, Sharma S, Brennan P, Roach H, Harper G, G\u00f3recki D (2006) Changes in immunolocalisation of \u03b2-dystroglycan and specific degradative enzymes in the osteoarthritic synovium. Osteoarthr Cartil 14(11):1181\u20131188. https:\/\/doi.org\/10.1016\/j.joca.2006.04.012","journal-title":"Osteoarthr Cartil"},{"issue":"11","key":"12545_CR90","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00467-005-2011-9","volume":"20","author":"PJ Thornalley","year":"2005","unstructured":"Thornalley PJ (2005) Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol 20(11):1515\u20131522. https:\/\/doi.org\/10.1007\/s00467-005-2011-9","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"12545_CR91","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/gerona\/glq074","volume":"65A","author":"RD Semba","year":"2010","unstructured":"Semba RD, Nicklett EJ, Ferrucci L (2010) Does accumulation of advanced glycation end products contribute to the aging phenotype? Journals Gerontol Ser A 65A(9):963\u2013975. https:\/\/doi.org\/10.1093\/gerona\/glq074","journal-title":"Journals Gerontol Ser A"},{"issue":"6","key":"12545_CR92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s001250050725","volume":"40","author":"T Soulis","year":"1997","unstructured":"Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Cooper ME, Murray-McIntosh RP (1997) Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40(6):619\u2013628. https:\/\/doi.org\/10.1007\/s001250050725","journal-title":"Diabetologia"},{"issue":"3","key":"12545_CR93","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jcla.21591","volume":"27","author":"Y Kurosaki","year":"2013","unstructured":"Kurosaki Y, Tsukushi T, Munekata S, Akahoshi T, Moriya T, Ogawa Z (2013) Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Anal 27(3):231\u2013236. https:\/\/doi.org\/10.1002\/jcla.21591","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"12545_CR94","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1615\/critrevoncog.2020035971","volume":"25","author":"V Sinha","year":"2020","unstructured":"Sinha V, Shinde S, Saxena S, Thakur S, Walia T, Dixit V, Tiwari AK, Vishvakarma NK, Dwivedi M, Shukla D (2020) A comprehensive review of diagnostic and therapeutic strategies for the management of pancreatic cancer. Crit Reviews\u2122 Oncog 25(4):381\u2013404. https:\/\/doi.org\/10.1615\/critrevoncog.2020035971","journal-title":"Crit Reviews\u2122 Oncog"},{"issue":"19","key":"12545_CR95","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sanagapalli S, Stoita A (2018) Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 24(19):2047\u20132060. https:\/\/doi.org\/10.3748\/wjg.v24.i19.2047","journal-title":"World J Gastroenterol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12545-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:18:17Z","timestamp":1785842297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12545-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12545"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12545-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1346"}}